Arbutus Biopharma Reports Executive Changes, Compensation on Dec 31
Ticker: ABUS · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $400, $515,000, $127,500 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Arbutus Biopharma just reported executive changes and compensation details from Dec 31, 2023.**
AI Summary
Arbutus Biopharma Corp filed an 8-K on January 4, 2024, reporting an event on December 31, 2023, related to changes in directors or officers and their compensation. This filing indicates potential shifts in leadership or executive pay structures, which could impact the company's strategic direction and financial performance. Investors should pay attention to these changes as they can signal future operational adjustments or a new focus for the company, potentially affecting stock valuation.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or financial health, directly influencing investor confidence and the company's future direction.
Risk Assessment
Risk Level: medium — Changes in executive compensation or leadership can introduce uncertainty regarding future company strategy and performance, posing a medium risk.
Analyst Insight
An investor should monitor subsequent filings or company announcements for specific details on the executive changes and compensation arrangements to assess their potential impact on the company's strategy and financial outlook.
Key Players & Entities
- Arbutus Biopharma Corp (company) — registrant filing the 8-K
- December 31, 2023 (date) — date of earliest event reported
- January 4, 2024 (date) — date the 8-K was filed
- 001-34949 (other) — Commission File Number
- 98-0597776 (other) — IRS Employer Identification No.
Forward-Looking Statements
- Arbutus Biopharma Corp will announce specific details regarding executive departures or appointments. (Arbutus Biopharma Corp) — medium confidence, target: Q1 2024
- The company will provide further clarity on new compensatory arrangements for officers. (Arbutus Biopharma Corp) — medium confidence, target: Q1 2024
FAQ
What was the specific date of the earliest event reported in this 8-K filing by Arbutus Biopharma Corp?
The earliest event reported in this 8-K filing by Arbutus Biopharma Corp occurred on December 31, 2023.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 4, 2024.
What items are specifically mentioned in the 'ITEM INFORMATION' section of this 8-K?
The 'ITEM INFORMATION' section mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
What is the business address of Arbutus Biopharma Corp as stated in the filing?
The business address of Arbutus Biopharma Corp is 701 Veterans Circle, Warminster, Pennsylvania, 18974.
What is the Commission File Number for Arbutus Biopharma Corp?
The Commission File Number for Arbutus Biopharma Corp is 001-34949.
Filing Stats: 911 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2024-01-04 16:09:10
Key Financial Figures
- $400 — ices, Mr. Collier will receive a fee of $400 per hour. Additionally, during the term
- $515,000 — n Mr. McElhaugh's annual base salary to $515,000 and an increase in Mr. McElhaugh's targ
- $127,500 — tled to an additional yearly stipend of $127,500, which shall be pro-rated monthly, and
Filing Documents
- abus-20231231.htm (8-K) — 35KB
- ex101abus-wcollierseparati.htm (EX-10.1) — 63KB
- ex102abus-wcollierconsulti.htm (EX-10.2) — 79KB
- ex103fourthamendmenttommem.htm (EX-10.3) — 18KB
- 0001447028-24-000006.txt ( ) — 353KB
- abus-20231231.xsd (EX-101.SCH) — 2KB
- abus-20231231_lab.xml (EX-101.LAB) — 23KB
- abus-20231231_pre.xml (EX-101.PRE) — 12KB
- abus-20231231_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Separation and Release Agreement, dated December 31, 2023, by and between William Collier and Arbutus Biopharma Corporation 10.2 Consulting Agreement, effective December 31, 2023, by and between William Collier and Arbutus Biopharma Corporation 10.3 Fourth Amendment to Executive Employment Agreement, dated January 1, 2024, by and between Michael McElhaugh and Arbutus Biopharma, Inc. 104 Cover page interactive data file (formatted as inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 4, 2024 ARBUTUS BIOPHARMA CORPORATION By: /s/ David C. Hastings Name: David C. Hastings Title: Chief Financial Officer